

Press release

14-03-2024



Genetic Analysis AS: Mandatory notification of trade – Primary Insider

OSLO, NORWAY – 14 March 2024: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares.

Christina Casén, SVP Clinical & Medical Affairs of Genetic Analysis AS, has yesterday Wednesday 13.03.2024 bought 16.500 GEAN shares at an average price of 0,61 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Christina Casén owns 176.989 shares and 210.000 options.

For further information, please contact:

Eilert Aamodt, CFO

E-mail: ea@genetic-analysis.com

About Genetic Analysis:

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.

For more general information: www.genetic-analysis.com

Stay updated on GA and sign up for more investor-related information: <https://www.genetic-analysis.com/subscriptions/>

Interested in reading more about GA's products? Please visit ga-map.com